RIDOV was tested against three significant bacteria mediums Golden Staph, Vancomycin-Resistant Enterococci (VRE), Methicillin-resistant Staphylococcus aureus (MRSA) commencing in 2011 and concluding 2013.
Conducted by Dr Kylie Wilson (Senior Technical Officer) and Dr Kunkun Zhang (Technical Officer) of MICROMON located at Building 75, Monash University, 3800 Clayton Campus, Wellington Road, and Clayton VICTORIA. Monash University Victoria’s clinical trials found RIDOV delivered a highly effective kill rate of 99.99% offering a protection cycle of 72 hours.
